Pfizer Pipeline

1 Pfizer Pipeline As of May 2, 2017 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information for some candidates in Phase 1 and for all candidates from Phase 2 through regulatory approval. With a view to expanding the transparency of our Pipeline , Pfizer is including new indications or enhancements, which target unmet medical need or represent significant commercial opportunities. The information contained on these pages is correct as of May 2, 2017. Visit , Pfizer s online database where you can learn more about our portfolio of new medicines and find out more about our Research and Development efforts around the world. 2 Table of Contents 3 Pfizer Pipeline Snapshot 4 Inflammation and Immunology 5 Metabolic Disease and Cardiovascular Risks 6 Neuroscience 7 Oncology 8-10 Rare Diseases 11 Vaccines 12 Biosimilars and Other Areas of Focus 13 Projects Discontinued Since Last Update 14 Backup.

2 Regulatory Designation Definitions 15-16 Pfizer Pipeline Snapshot 4 Pipeline represents progress of R&D programs as of January 31, 2017 Included are 62 NMEs, 26 additional indications, plus 8 biosimilars Phase 2 Phase 3 Registration 36 17 32 11 Phase 1 Total 96 Discovery Projects 9 programs advanced or are new Pipeline represents progress of R&D programs as of May 2, 2017 Included are 61 NMEs, 27 additional indications, plus 8 biosimilars 1 project discontinued since last update Phase 2 Phase 3 35 20 34 7 Phase 1 Total 96 Discovery Projects 11 programs advanced or are new 3 projects discontinued since last update Pfizer Pipeline Snapshot as of May 2, 2017 Pfizer Pipeline Snapshot as of January 31, 2017 Registration Recent Approvals -Bavencio (avelumab) for Merkel Cell Carcinoma (US) -Xeljanz (tofacitinib) for Rheumatoid Arthritis (EU) Recent Approvals - Eucrisa (crisaborole) for Atopic Dermatitis (US) - Ibrance (palbociclib) for the Treatment of Women with HR+/HER2- Metastatic Breast Cancer (EU) New Molecular Entity New Indication or Enhancement Pfizer Pipeline May 2, 2017 (cont d) 5 * Note.

3 Additional indications in Phase 1 Therapeutic AreaCompound NameMechanism of ActionIndicationPhaseXeljanz (tofacitinib)JAK InhibitorUlcerative Colitis Phase 3 Xeljanz (tofacitinib)JAK InhibitorPsoriatic ArthritisPhase 3 DekavilIL-10 Rheumatoid Arthritis, *Inflammatory Bowel Disease (Biologic)Phase 2PF-04965842 JAK InhibitorAtopic DermatitisPhase 2PF-06480605 TNFSF15 BlockerUlcerative Colitis (Biologic)Phase 2PF-06650833 IRAK4 Rheumatoid ArthritisPhase 2PF-06651600 JAK3 Alopecia Areata, Rheumatoid Arthritis, Ulcerative ColitisPhase 2PF-06700841 TYK2/JAK1 Alopecia Areata, Psoriasis, Ulcerative ColitisPhase 2PF-06342674interleukin 7 receptor precursor ModulatorDiabetes Mellitus-Type 1 (Biologic)Phase 1PF-06423264acetyl-Coenzyme A carboxylase alpha+beta InhibitorAcnePhase 1PF-06817024 Cytokine ModulatorAtopic Dermatitis (Biologic)Phase 1PF-06823859interferon, beta 1, fibroblast (IFNB1) BlockerLupus (Biologic)Phase 1 InflammationandImmunology Pfizer Pipeline May 2, 2017 6 New Molecular Entity Indicates that the project is either new or has progressed in phase since the previous portfolio update of Therapeutic AreaCompound NameMechanism of ActionIndicationPhase ertugliflozin (PF-04971729)SGLT-2 InhibitorDiabetes Mellitus-Type 2 RegistrationPF-05221304 Acetyl CoA-Carboxylase (ACC) InhibitorNon-Alcoholic Steatohepatitis (NASH)

4 Phase 1PF-06282999 Myeloperoxidase InhibitorAcute Coronary SyndromePhase 1PF-06293620 Glucagon Receptor BlockerDiabetes Mellitus-Type 2 (Biologic)Phase 1PF-06427878 Diacylglycerol O-Acyltransferase 2 (DGAT2) InhibitorHyperlipidemiaPhase 1PF-06835919 Ketohexokinase (KHK) InhibitorNon-Alcoholic Steatohepatitis (NASH)Phase 1 PF-06865571 Diacylglycerol O-Acyltransferase 2 (DGAT2) InhibitorNon-Alcoholic Steatohepatitis (NASH)Phase 1 Metabolic DiseaseandCardiovascular Risks Pfizer Pipeline May 2, 2017 (cont d) 7 New Molecular Entity New Indication or Enhancement Indicates that the project is either new or has progressed in phase since the previous portfolio update of Therapeutic AreaCompound NameMechanism of ActionIndicationPhase LyricaAlpha-2 Delta LigandCR (once a day dosing)RegistrationtanezumabNerve Growth Factor InhibitorOA Signs and Symptoms, Chronic Low Back Pain, Cancer Pain (Biologic)Phase 3PF-06372865 GABA A Receptor AgonistEpilepsyPhase 2PF-06649751 Dopamine 1 activatorParkinson's DiseasePhase 2PF-04958242 AMPA Ion ChannelSchizophreniaPhase 1PF-05251749 Combination.

5 Casein kinase I delta/epsilonAlzheimer s DiseasePhase 1PF-06648671 Gamma secretase complex ModulatorAlzheimer s DiseasePhase 1PF-06669571 Dopamine 1 activatorCognitive DisorderPhase 1PF-06751979 Enzyme InhibitorAlzheimer's DiseasePhase 1PF-06818883monoglyceride lipase (MGLL) InhibitorIntracerebral HemorrhagePhase 1 Neuroscience Pfizer Pipeline May 2, 2017 (cont d) 8 New Molecular Entity New Indication or Enhancement Indicates Regulatory Designation See Definitions in Backup Indicates that the project is either new or has progressed in phase since the previous portfolio update of Therapeutic AreaCompound NameMechanism of ActionIndicationPhaseBavencio (avelumab)Anti PD-L1 Inhibitor2nd Line Metastatic Merkel Cell Carcinoma ( ) (Biologic)Registration Bavencio (avelumab)Anti PD-L1 Inhibitor2nd Line Urothelial Carcinoma (Biologic) (PRIORITY REVIEW - )Registration inotuzumab ozogamicin CD22-targeted cytotoxic agent Acute Lymphoblastic Leukemia (Biologic) (BREAKTHROUGH, PRIORITY REVIEW - , ORPHAN - , )RegistrationMylotargCD33-targeted cytotoxic agent1st Line Acute Myeloid Leukemia (Biologic)Registration Sutent (sunitinib)Multiple Tyrosine Kinase InhibitorRenal Cell Carcinoma Adjuvant ( )RegistrationBavencio (avelumab)Anti PD-L1 Inhibitor2nd Line Non-Small Cell Lung Cancer (Biologic)Phase 3 Bavencio (avelumab)Anti PD-L1 Inhibitor1st Line Non-Small Cell Lung Cancer (Biologic)Phase 3 Bavencio (avelumab)Anti PD-L1 Inhibitor1st Line Gastric Cancer (Biologic)Phase 3 Bavencio (avelumab)

6 Anti PD-L1 Inhibitor3rd Line Gastric Cancer (Biologic)Phase 3 Bavencio (avelumab)Anti PD-L1 InhibitorPlatinum Resistant/Refractory Ovarian Cancer (Biologic)Phase 3 Bavencio (avelumab)Anti PD-L1 Inhibitor1st Line Ovarian Cancer (Biologic)Phase 3 Bavencio (avelumab)Anti PD-L1 Inhibitor1st Line Urothelial Cancer (Biologic)Phase 3 Bavencio (avelumab)Anti PD-L1 Inhibitor1st Line Renal Cell Carcinoma (Biologic) (Combo w/ Inlyta (axitinib))Phase 3 Bavencio (avelumab)Anti PD-L1 InhibitorLocally Advanced Squamous Cell Carcinoma of the Head and Neck (Biologic)Phase 3 Bosulif (bosutinib)Abl and src-family Kinase Inhibitor1st Line Chronic Myelogenous Leukemia (ORPHAN - )Phase 3 Oncology(1 of 3) Pfizer Pipeline May 2, 2017 (cont d) 9 New Molecular Entity New Indication or Enhancement * Note.

7 Additional indications in Phase 1 Therapeutic AreaCompound NameMechanism of ActionIndicationPhasedacomitinib (PF-00299804)pan-HER Inhibitor1st Line EGFR-activating mutant Non-Small Cell Lung Cancer (ORPHAN - )Phase 3 Ibrance (palbociclib)CDK 4,6 Kinase InhibitorHigh Risk Early Breast CancerPhase 3 Ibrance (palbociclib)CDK 4,6 Kinase InhibitorEarly Breast Cancer in Adjuvant Setting, *CancerPhase 3 Inlyta (axitinib)VEGF Tyrosine Kinase InhibitorRenal Cell Carcinoma Adjuvant, *Cancer combo w/ Merck s Keytruda (PD-1, pembrolizumab), *Combo w/ Xalkori for RCCP hase 3 lorlatinib (PF-06463922)ALK InhibitorALK Non-Small Cell Lung Cancer (BREAKTHROUGH, ORPHAN - )Phase 3 Sutent (sunitinib)Multiple Tyrosine Kinase InhibitorRenal Cell Carcinoma Adjuvant ( )Phase 3talazoparib (MDV3800)PARP inhibitorGermline BRCA Mutated Metastatic Breast CancerPhase 3 Xtandi (enzalutamide)Androgen receptor inhibitorMetastatic Hormone Sensitive Prostate CancerPhase 3 Xtandi (enzalutamide)Androgen receptor inhibitorNon-metastatic Castrate Resistant Prostate CancerPhase 3 Xtandi (enzalutamide)Androgen receptor inhibitorNon-metastatic High Risk Hormone Sensitive Prostate CancerPhase 3 Xtandi (enzalutamide)Androgen receptor inhibitorTriple Negative Breast CancerPhase 3 Bavencio (avelumab)Anti PD-L1 Inhibitor1st Line Merkel Cell Carcinoma ( ), *Cancer, Combo w/ PF-05082566 (41BB) for.

8 Non-Small Cell Lung Cancer, Triple-Negative Breast Cancer, Squamous Cell Carcinoma of the Head and Neck, Melanoma (Biologic)Phase 2glasdegib (PF-04449913)SMO (smoothened) antagonistAcute Myeloid Leukemia, *CancerPhase 2 Oncology(2 of 3)Indicates Regulatory Designation See Definitions in Backup Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer Pipeline May 2, 2017 (cont d) 10 New Molecular Entity New Indication or Enhancement Therapeutic AreaCompound NameMechanism of ActionIndicationPhaseIbrance (palbociclib)CDK 4,6 Kinase InhibitorSquamous Cell Carcinoma of the Head and NeckPhase 2 Xtandi (enzalutamide)Androgen receptor inhibitorER/PR+ & HER2 normal Breast Cancer; AR+, HER2+ amplified Breast Cancer.

9 Hepatocellular CarcinomaPhase 2gedatolisib (PF-05212384)Phosphatidyl inositol-3 kinase catalytic sub-unit inhibitor / mammalian target of rapamycin inhibitor (PI3K/mTOR)CancerPhase 1PF-04136309 CCR2 (Chemokine receptor 2) AntagonistPancreatic CancerPhase 1PF-04518600OX40 receptor AgonistCancer, Combo w/ avelumab (PD-L1) (Biologic)Phase 1PF-05082566CD137 AgonistCancer (Biologic), Combo w/ Merck s Keytruda (PD-1, pembrolizumab), Combo w/ Kyowa Hakko Kirin s anti-CCR4 antibody (mogamulizumab)Phase 1PF-06647020protein tyrosine kinase 7 (PTK7) Targeted CytotoxicityCancer (Biologic)Phase 1PF-06647263ephrin-A4 (EFNA4) Targeted CytotoxicityCancer (Biologic)Phase 1PF-06671008cadherin 3, type 1, P-cadherin (placental) (CDH3)Cancer (Biologic)Phase 1PF-06747143chemokine (C-X-C motif) receptor 4 (CXCR4) InhibitorAcute Myeloid Leukemia (Biologic)Phase 1PF-06747775epidermal growth factor receptor (erythroblastic)CancerPhase 1PF-06801591programmed cell death 1 (PDCD1) AntagonistCancer Immunotherapy (Biologic)Phase 1PF-06840003indoleamine 2,3-dioxygenase 1 (IDO1) InhibitorCancerPhase 1PF-06883541CD19 molecule Targeted CytotoxicityCancer (Biologic)Phase 1 Oncology(3 of 3) New Molecular Entity Pfizer Pipeline May 2, 2017 (cont d) 11 New Indication or Enhancement Indicates Regulatory Designation See Definitions in Backup ** Note: Two EU orphan designations apply to Vyndaqel in cardiomyopathy.

10 One for patients with familial amyloid cardiomyopathy due to a genetic variant of the TTR gene(TTR-FAC), and another EU orphan designation for senile systemic amyloidosis, for cardiomyopathy in patients without the gene variant (TTR-Wild Type). Therapeutic AreaCompound NameMechanism of ActionIndicationPhasetafamidis meglumine Transthyretin (TTR) Dissociation InhibitorTransthyretin familial amyloid polyneuropathy ( ) (FAST TRACK, ORPHAN - )Registrationrivipansel (GMI-1070) Pan-Selectin AntagonistVaso-occlusive crisis associated with Sickle Cell Disease (FAST TRACK, ORPHAN - , )Phase 3somatrogon (PF-06836922) (MOD-4023)Human Growth Hormone AgonistAdult Growth Hormone Deficiency (Biologic) (ORPHAN - , )Phase 3 Vyndaqel (tafamidis meglumine)Transthyretin (TTR) Dissociation InhibitorAdult Symptomatic Transthyretin Cardiomyopathy (ORPHAN - , **)Ph